Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.
about
Prospects for vaccine prevention of meningococcal infectionImmune response induction and new effector mechanisms possibly involved in protection conferred by the Cuban anti-meningococcal BC vaccinePreventative strategies on meningococcal diseaseVaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysisStandardization of Neisseria meningitidis serogroup B colorimetric serum bactericidal assayCan Neisseria lactamica antigens provide an effective vaccine to prevent meningococcal disease?Solution structure of the immunodominant domain of protective antigen GNA1870 of Neisseria meningitidis.Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.Identification and characterization of TspA, a major CD4(+) T-cell- and B-cell-stimulating Neisseria-specific antigen.Vaccines against meningococcal disease: current and future technologies.Auto-transporter A protein of Neisseria meningitidis: a potent CD4+ T-cell and B-cell stimulating antigen detected by expression cloning.Use of transformation to construct antigenic hybrids of the class 1 outer membrane protein in Neisseria meningitidis.Review of meningococcal group B vaccines.Clonal distribution of disease-associated and healthy carrier isolates of Neisseria meningitidis between 1983 and 2005 in CubaImmune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.Meningococcal disease in healthcare workers. Vaccine is available in Latin America.Update on meningococcal disease with emphasis on pathogenesis and clinical managementHumoral immune responses to Neisseria meningitidis in children.Cellular immune responses to Neisseria meningitidis in childrenT-cell-stimulating protein A elicits immune responses during meningococcal carriage and human disease.Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team.Serosubtypes and PorA types of Neisseria meningitidis serogroup B isolated in Brazil during 1997--1998: overview and implications for vaccine development.Active immunization in the United States: developments over the past decade.Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature.Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infectionImmunization with recombinant Opc outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci.Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine.Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.Immunization with the recombinant PorB outer membrane protein induces a bactericidal immune response against Neisseria meningitidis.Three doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults.Primary care provision of specialist services.Telemedicine: 'communication' by any other name?Keeping the meningococcus out of the media.In silico studies of outer membrane of Neisseria meningitidis por a: its expression and immunogenic propertiesProspects offered by genome studies for combating meningococcal disease by vaccination.Construction of Opa-positive and Opa-negative strains of Neisseria meningitidis to evaluate a novel meningococcal vaccine.Immune responses in humans and animals to meningococcal transferrin-binding proteins: implications for vaccine design.Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy.The meningococcus tamed?Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine
P2860
Q24537338-848D4676-E266-4FBA-A989-7113C686944DQ24548670-9C3757E5-0EF6-4AEF-B641-4A1B8D07F7D2Q24676339-55EE1555-04B8-4BEA-8451-1F74E772DEF6Q26779489-5050315A-0955-4CAB-9BAD-74BB5954DB0EQ28344521-186E3231-ED4A-459E-904C-627304CC8C5DQ30150784-D6E60F43-0F12-4DB4-8D39-70F60B9D9F48Q30159962-1B5163EC-B576-4602-8BDB-E010D08D86EFQ30227840-F7691B0D-15E2-4241-906E-01175A48344AQ30720717-E8FD7AF6-C1FC-4CA5-8CD8-F7AC98A36AA9Q30771493-FC553CA8-695A-4A2B-834A-EACB28AC786AQ31806487-51D1D942-0461-4B89-B3FD-17BD6AECAA6BQ33610780-602F2DC4-3301-42AE-8BED-1C9A2853409DQ33646965-29F90EBD-0D57-472A-83E9-3F5B32C14A3BQ33704817-F5E64BCE-20DD-4D77-8A69-07DD937619FAQ33756300-70DF9C28-96CB-48EF-8C69-4B6D1CEF6974Q33799641-39EB9427-E80B-4C36-8191-6332D8C94FE2Q33812435-1B8F7B31-2187-4833-8659-BD01471B1A50Q33867340-04B30AF2-4EFC-489F-8324-09DA80E4B93DQ33867356-F2EA48BD-440F-4103-B3FB-23897A21F927Q33946678-CA1D0A71-4578-4158-96DB-586AADD5D712Q33969625-2E40E235-2A6F-4FC1-9D95-EA552B08694EQ33973163-8ACDD82D-67BB-40D8-B95F-9912DD7E8E4CQ33975799-B42C7044-DF01-4EF1-8F62-FEA75AAC1F6BQ33999628-A982E727-094E-4AEF-9F48-03373A97F1D4Q34006346-BE4526BB-3F0B-4189-9548-AE87FA47744DQ34007787-B5B599CA-05F8-43A9-B857-7DD9C36F2731Q34116994-05F441CF-6B16-49A3-A5EC-1238732AA125Q34118124-1B8CCD94-A740-4252-9E73-DC471C68AA63Q34127607-2F120DFF-D629-418B-9E51-668028FC20EDQ34150340-02DB3D49-D39A-419E-913A-FB3ABBA4EC62Q34214286-F4CA59D4-EA36-4F55-8A52-04392E0F4C2BQ34214294-2D29F05E-FD7B-48E8-BF0E-CF03BF18149DQ34214301-54140700-B0CC-4BA4-B9E6-F963DB6E7817Q34221093-D4674974-8204-4E29-8BD1-87F9730A53EFQ34355276-4D5EA685-24F9-40F4-90F0-B33BBA708E86Q34516060-C86C56BB-E468-4317-8F71-25EA766FF5BFQ34530695-2D504173-E668-41E1-B5C3-0FA95F03CD50Q34541047-BC6E2BBF-05A7-42E9-ACF2-0FA5B44B5055Q34712881-CF1CFFDF-7650-4FF7-B98F-2259F717B3BDQ34720380-F2CA01CD-642D-4FF7-A2A6-165475282449
P2860
Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.
@en
Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.
@nl
type
label
Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.
@en
Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.
@nl
prefLabel
Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.
@en
Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.
@nl
P2093
P1433
P1476
Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.
@en
P2093
B A Perkins
C T Sacchi
H A Barbosa
H de G Vasconcelos
I M Landgraf
J C de Moraes
M C Camargo
N T Hidalgo
V L Gattas
P304
P356
10.1016/0140-6736(92)93086-3
P407
P577
1992-10-01T00:00:00Z